ArticleFrontiers in oncology2025
CT radiomics analysis facilitates preoperative risk stratification of central lymph node metastasis in papillary thyroid cancer: a multicenter study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early prediction of immunotherapy efficacy for advanced NSCLC based on clinical and pre-treatment contrast-enhanced CT radiomics features.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale and objectives: To develop a CT-based radiomics model to predict central lymph node metastasis (CLNM) in papillary thyroid cancer (PTC) patients and classify risk. Materials and methods: 218 PTC patients from institution 1 were retrospectively enrolled and randomly assigned to a training set and an internal test set (ratio 7:3). Another 64 patients from institution 2 were assigned to an independent test set. Radiomics features were extracted from the arterial phase CT images of PTC. A radiomics signature (Rad-score) was developed using the least absolute shrinkage and selection operator (LASSO) method. Three models, combined model, clinical model, and Rad-score, were established by logistic regression analysis. These models were comprehensively assessed by the area under the receiver operating characteristic curve (AUC), the calibration curve, and the decision curve analysis (DCA). The improvement in predictive efficacy of the combined nomogram was evaluated using the integrated discrimination improvement index (IDI) and net reclassification improvement index (NRI). The defined threshold of the predicted risk score was set at 0.5, and the stratification effect of the combined nomogram was evaluated by subgroup analysis. Results: The Rad-score and another three independent predictors (tumor margin, thyroid capsule state and tumor site) were integrated into a combined nomogram. The AUCs of the combined nomogram were 0.848, 0.858, and 0.840 in the training, internal test, and external test sets, respectively, which were greater than those of the clinical model and the Rad-score. The IDI and NRI were greater than 0 indicating better discriminatory accuracy of the combined nomogram than the clinical nomogram and Rad-score. The net benefit of the combined nomogram in the clinical setting was reflected in the DCA. The combined model allows for the effective stratification of patients in diverse risk subgroups. Conclusion: Combining Rad-score and clinical predictors in an integrated model allow for more accurate prediction of CLNM in PTC patients and enables effective risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.